List of Excipients in Branded Drug QUTENZA

Qutenza Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Qutenza is an 8% capsaicin topical system for neuropathic pain. Its commercial differentiation comes from the delivery system, controlled exposure, application procedure, and clinic-based administration rather than from a novel excipient. The strongest excipient opportunities are silicone-adhesive optimization, capsaicin stabilization and uniformity, cleansing-gel improvement, packaging, and alternative high-loading topical systems.

Qutenza was approved by the FDA in 2009 for neuropathic pain associated with postherpetic neuralgia and received an expanded indication in 2020 for neuropathic pain associated with diabetic peripheral neuropathy of the feet.[1,2] The product is marketed in the United States by Averitas Pharma, a Grünenthal company.

What excipients are used in Qutenza?

Qutenza uses a capsaicin-loaded silicone adhesive matrix applied through a polyester-backed topical system. The product is supplied with a cleansing gel used after treatment to remove residual capsaicin from the skin.[1]

Product component	Function	Commercial relevance
Capsaicin, 8% w/w	Active pharmaceutical ingredient	Requires uniform distribution and controlled topical delivery
Silicone adhesive matrix	Holds capsaicin in the topical system and enables skin contact	Central to adhesion, dose transfer, removal, and manufacturing
Polyester backing film	Structural support and handling layer	Controls flexibility, die-cutting, packaging, and application
Carbomer homopolymer Type C in cleansing gel	Gel-forming and viscosity-building agent	Controls spreadability and removal performance
Purified water in cleansing gel	Aqueous vehicle	Affects gel consistency and microbial control
Polysorbate 20 in cleansing gel	Surfactant and wetting agent	Supports removal of residual capsaicin
Sodium hydroxide in cleansing gel	pH adjustment and carbomer neutralization	Controls viscosity and skin compatibility
Disodium edetate in cleansing gel	Chelating agent	Supports formulation stability and preservative performance

The FDA labeling identifies the topical system as a silicone adhesive containing capsaicin with a polyester backing film. The cleansing gel contains carbomer homopolymer Type C, purified water, polysorbate 20, sodium hydroxide, and disodium edetate.[1]

The excipient system is deliberately limited. Qutenza does not depend on a complex emulsion, penetration-enhancing solvent package, liposomal carrier, or biodegradable polymer. That simplicity reduces formulation breadth but concentrates technical risk in the adhesive matrix and the treatment workflow.

How does Qutenza deliver capsaicin?

Qutenza delivers a high local capsaicin dose during a controlled application period, typically 60 minutes for the feet and 30 minutes for other areas.[1] The treatment is administered by a healthcare professional because capsaicin exposure can cause intense burning and must be managed with procedural controls.

The delivery architecture has four technical requirements:

The silicone matrix must hold approximately 8% capsaicin without crystallization, migration, or dose nonuniformity.
The adhesive must maintain sufficient skin contact throughout treatment.
The system must release capsaicin consistently across the labeled application period.
The product must be removable without leaving excessive capsaicin residue or causing avoidable skin trauma.

This structure gives Qutenza a different development profile from a conventional capsaicin cream. A cream must optimize spreadability, residence time, permeation, and patient handling. Qutenza must optimize matrix loading, adhesion, release, patch handling, and occupational safety.

What is the excipient strategy behind Qutenza?

Silicone adhesive matrix

The silicone adhesive is the core formulation platform. It must function as both a dosage-form carrier and a skin-contact adhesive. High capsaicin loading can alter adhesive cohesion, tack, viscoelasticity, and drug migration.

Important development variables include:

silicone polymer molecular weight and crosslink density;
capsaicin particle size and physical state;
mixing temperature and shear;
coating thickness;
residual solvents, if used in manufacturing;
release-liner compatibility;
capsaicin crystallization during storage;
adhesion after exposure to sweat, oils, or hair.

A reformulated product that changes the silicone grade, curing chemistry, or coating process could require extensive comparability work. The sponsor would need to demonstrate consistent capsaicin content, content uniformity, adhesive performance, in vitro release, stability, and clinical performance where the change affects exposure.

Polyester backing

The backing film is not pharmacologically active, but it affects handling and manufacturing. It must provide dimensional stability during coating, die-cutting, packaging, and application. Film thickness, tensile strength, opacity, and barrier characteristics can affect dose protection and operator handling.

A higher-barrier backing could reduce capsaicin migration into packaging. A more flexible film could improve conformity to the foot or other anatomical areas. A patterned or segmented backing could improve application alignment but would introduce new manufacturing and human-factors requirements.

Cleansing gel

The cleansing gel is a functional part of the product kit. Its commercial value is higher than its low-cost ingredient profile suggests because it helps control residual capsaicin after removal.

Carbomer provides viscosity and skin residence. Polysorbate 20 assists wetting and solubilization of capsaicin residues. Sodium hydroxide neutralizes the carbomer and adjusts pH. Disodium edetate supports chemical stability by binding trace metal ions.[1]

Potential optimization areas include:

faster removal of residual capsaicin;
reduced wiping force;
lower skin irritation;
lower transfer to healthcare workers;
improved compatibility with gloves and clinical surfaces;
single-dose packaging;
improved dosing of gel per treated area.

A replacement cleansing gel would be subject to compatibility, stability, skin irritation, microbiological, and performance testing. The sponsor would need to show that the revised gel does not increase residual capsaicin exposure or alter the safety profile.

What formulation patents protect Qutenza?

The most defensible protection for Qutenza is likely to reside in the combination of formulation know-how, manufacturing controls, application procedures, packaging, and clinical/regulatory data rather than in broad exclusivity over capsaicin itself.

Capsaicin is an old active ingredient. Broad composition claims covering capsaicin topical products face substantial prior-art exposure. Potentially protectable subject matter includes:

high-loading capsaicin silicone matrices;
specific adhesive compositions;
capsaicin particle-size distributions;
coating and curing processes;
multilayer backing structures;
low-migration packaging;
cleansing systems designed for high-dose capsaicin removal;
application methods for diabetic peripheral neuropathy;
treatment protocols that reduce procedural adverse effects.

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity associated with an approved drug product.[3] Qutenza’s competitive position should not be assessed solely through historical capsaicin patents. Expired foundational patents do not prevent development of a new product, while unlisted manufacturing know-how can still create meaningful commercial barriers.

When does Qutenza lose exclusivity?

Qutenza received FDA approval under NDA 022395 in 2009. The diabetic peripheral neuropathy indication was approved in 2020 through a supplemental application.[1,2]

Protection category	Qutenza position
FDA approval	Original approval in 2009
Expanded indication	Diabetic peripheral neuropathy of the feet approved in 2020
Chemical exclusivity	Not applicable in the conventional new-chemical-entity sense because capsaicin is an established active
Biologic exclusivity	Not applicable
Orphan-drug exclusivity	Not the principal protection described in the product labeling
Patent protection	Must be evaluated through current Orange Book listings and relevant formulation, process, and method-of-use records
Main remaining barrier	Complex topical-system development, clinical evidence, manufacturing scale-up, and healthcare-provider adoption

Because capsaicin is an established molecule, Qutenza does not have the same exclusivity profile as a recently approved chemical entity. The key generic-entry question is whether a competitor can obtain approval for an equivalent high-dose topical system, or whether it must pursue a 505(b)(2) pathway supported by bridging studies and new clinical evidence.

Is Qutenza vulnerable to Paragraph IV challenges?

A conventional ANDA challenge may be difficult because Qutenza is not a simple cream, ointment, or solution. An ANDA applicant would need to address:

qualitative and quantitative composition;
adhesive and backing materials;
capsaicin distribution;
in vitro release;
adhesion and wear performance;
residual drug after removal;
packaging and stability;
labeling and application instructions.

A 505(b)(2) applicant could develop a different capsaicin topical system and rely partly on FDA findings for capsaicin while generating bridging data for the new delivery system. That route may be more realistic for a reformulated patch, film, gel, or other high-dose topical product.

Paragraph IV litigation would depend on the existence of unexpired listed patents. Method-of-use patents could create narrower litigation risk than formulation patents because a competitor may attempt a carve-out for a patented indication. A product with a different dosage form would face patent and regulatory questions separately from the Qutenza label.

What generic entry risks exist for Qutenza?

Qutenza faces three distinct competitive risks.

Generic topical-system risk

A competitor could develop a patch with the same active ingredient and comparable performance. The principal barrier would be manufacturing reproducibility rather than ingredient sourcing. Capsaicin is widely available, but a consistent 8% silicone matrix with acceptable release and adhesion is more difficult to reproduce.

505(b)(2) reformulation risk

A new product could use a different adhesive, film, gel, or topical delivery technology. This product might compete without duplicating every Qutenza excipient. A 505(b)(2) application could support a differentiated label, shorter application time, improved tolerability, or home-use administration.

Substitution by lower-cost products

Capsaicin creams and over-the-counter topical products are cheaper and easier to distribute. They do not provide the same high-dose, clinic-administered exposure, but they compete for patients, prescriber attention, and payer budgets.

What commercial opportunities exist in Qutenza excipients?

Can a lower-irritation cleansing gel improve Qutenza?

Yes. A redesigned cleansing gel could target procedural safety and clinic efficiency. Candidate strategies include optimized surfactant blends, controlled viscosity, lower-irritation pH, improved wipeability, and unit-dose packaging.

The commercial objective would not be to increase capsaicin penetration. It would be to remove residual capsaicin more rapidly and reduce transfer to staff, clothing, treatment surfaces, and untreated skin.

Can a new adhesive improve application?

A next-generation silicone or hybrid adhesive could target better conformity to the foot, fewer edge lifts, and more consistent skin contact. Adhesive changes must avoid excessive tack because aggressive removal can increase discomfort and skin injury.

An adhesive improvement could support a product extension with shorter application time if the revised matrix demonstrates faster or more efficient capsaicin delivery. That claim would require clinical substantiation and would not follow automatically from a formulation change.

Can Qutenza be adapted for home use?

Home use is a major commercial opportunity but also the highest-risk product extension. The current clinical model reflects the irritant nature of 8% capsaicin. A home-use product would need safer handling, simplified application, dose-limiting features, improved residue control, and clear instructions for avoiding eye and mucosal exposure.

A lower-dose, smaller-area, or premeasured disposable system may be more commercially practical than transferring the existing clinic procedure directly to the home.

Can packaging create value?

Packaging can protect the matrix from capsaicin migration, moisture, oxygen, heat, and mechanical damage. Individual foil pouches, barrier laminates, tamper-evident features, and disposal systems can reduce occupational exposure.

Packaging patents and trade secrets may be commercially relevant even when the active ingredient and core excipients are old. The strongest protection would cover a tested combination of matrix, pouch, storage condition, and handling procedure.

How does Qutenza compare with competing capsaicin products?

Attribute	Qutenza	Low-dose capsaicin cream or OTC product
Capsaicin concentration	8%	Generally much lower
Administration	Healthcare professional	Patient or caregiver
Treatment pattern	Intermittent, controlled application	Repeated self-application
Excipient priority	Adhesive matrix and cleansing gel	Vehicle, penetration, spreadability, preservation
Regulatory pathway for a new competitor	ANDA may be difficult; 505(b)(2) likely for a different system	Conventional generic or OTC pathways may be more accessible
Commercial advantage	High-dose clinic treatment and reduced daily application burden	Lower cost and broader access
Main safety issue	Intense application-site burning and exposure control	Repeated use, adherence, and variable application

Qutenza competes less directly with injectable biologics or systemic neuropathic-pain medicines than with topical capsaicin products and clinic-based pain interventions. Biosimilar risk is irrelevant because Qutenza is a small-molecule topical system, not a biologic.

What is Qutenza’s revenue exposure?

Public financial disclosures do not generally provide a standalone Qutenza revenue line. The product’s economic value is therefore best assessed through market access, treatment volume, payer coverage, clinic capacity, and repeat-treatment frequency rather than a publicly disclosed product-specific revenue figure.

The commercial model has several characteristics:

revenue is linked to procedure capacity and specialist adoption;
clinic administration increases labor and handling costs;
high unit pricing can be offset by payer restrictions;
repeat treatment supports recurring demand;
treatment-center workflow affects product utilization;
a safer or faster cleansing and application process could improve throughput.

Excipient innovation has the greatest commercial value when it improves one of these operational metrics: treatment time, staff safety, application consistency, storage, waste, or patient tolerability.

What manufacturing and IP barriers affect Qutenza competitors?

The main manufacturing barriers are process control and scale-up. Critical controls include capsaicin dispersion, coating uniformity, adhesive curing, die-cut accuracy, pouch sealing, and stability testing.

A competitor may be able to source the same active ingredient and similar excipients but still fail to match:

drug content uniformity across the full topical system;
adhesive performance over the treatment period;
release consistency;
long-term physical stability;
resistance to capsaicin migration;
worker exposure controls;
batch-to-batch appearance and handling.

These barriers support trade-secret protection. A sponsor can also seek patents around specific matrix compositions, coating methods, packaging assemblies, cleansing formulations, and use protocols.

Key Takeaways

Qutenza is an 8% capsaicin silicone-adhesive topical system with a polyester backing and a separate cleansing gel.
Its most important excipient is the silicone adhesive matrix because it controls dose distribution, adhesion, release, and removal.
The cleansing gel is a practical product-development target because it affects residual capsaicin exposure, staff safety, and clinic workflow.
Capsaicin itself has limited composition-of-matter value because it is an established active ingredient.
Generic entry is technically more difficult than for a conventional capsaicin cream, but a 505(b)(2) reformulation could create meaningful competition.
Home-use systems, faster-acting patches, lower-irritation cleansing products, improved packaging, and alternative adhesive matrices are the strongest commercial opportunity areas.
Qutenza has no biosimilar risk. Its main competitive risks are topical-system duplication, 505(b)(2) reformulation, lower-cost capsaicin products, and payer or clinic adoption constraints.
Manufacturing know-how and process patents may be more important than broad active-ingredient patents.

FAQs

What is the most valuable excipient innovation for Qutenza?

The highest-value opportunity is a silicone adhesive matrix that improves capsaicin uniformity, skin conformity, release control, and removal without increasing irritation.

Could a competitor replace Qutenza’s cleansing gel with a different formulation?

Yes. A competitor could develop a different post-treatment cleansing formulation, but it would need to demonstrate adequate capsaicin removal, skin compatibility, stability, packaging compatibility, and clinical safety.

Is Qutenza an extended-release product?

Qutenza is a controlled topical delivery system, but it should not be characterized as a conventional oral extended-release dosage form. Its performance depends on high local capsaicin exposure during a defined application period.

Could a capsaicin hydrogel compete with Qutenza?

Yes. A capsaicin hydrogel could compete through a 505(b)(2) pathway if it offers a differentiated dose, application time, delivery profile, or administration setting. It would not automatically be substitutable for Qutenza.

What excipient changes could support a Qutenza lifecycle product?

Potential lifecycle changes include a new silicone adhesive, a smaller or anatomically shaped topical system, a redesigned cleansing gel, unit-dose packaging, improved barrier packaging, and a formulation intended for shorter or supervised home administration.

References

U.S. Food and Drug Administration. (2023). Qutenza (capsaicin) topical system: Prescribing information. Averitas Pharma, Inc.
U.S. Food and Drug Administration. (2020). FDA approves Qutenza for diabetic peripheral neuropathy of the feet. https://www.fda.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

More… ↓

⤷ Start Trial